until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.SUBJECT TO COMPLETION, DATED OCTOBER 5, 2004PROSPECTUS3,438,627 SharesCommon StockThe selling stockholders identified in this prospectus are offering for sale up to 3,438,627 shares of our Common Stock, $0.01 par value per
The selling stockholders have indicated that sales of their shares of Common Stock may be made by the methods described in the section entitled "Plan of Distribution" in this prospectus.The
The shares may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective.The date of this prospectus is            , 2004TABLE OF CONTENTSPageProspectus Summary1Risk Factors3Forward-Looking Information17Use of Proceeds18Price Range of Common Stock18Selected Consolidated Financial Data19Management's Discussion and Analysis of Financial Condition and Results of Operations20Business33Management54Stock Performance Graph61Related Party Transactions63Principal Stockholders64Description of Capital Stock67Selling Stockholders71Plan of Distribution75Legal Matters77Experts77Where You Can Find More Information77Index to Consolidated Financial StatementsF-1The names "Acusphere," "HDDS" and "PDDS" and our logo are our trademarks.
the risk factors and consolidated financial statements and related notes included in this prospectus.Our CompanyWe are a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using our proprietary porous microparticle
AI-700 and, subject to required regulatory approvals, we intend to manufacture AI-700 in this facility for commercial use.Private FinancingIn July 2004, we entered into definitive purchase agreements with institutional and accredited investors for a $21.5 million private placement of up
assurance that hospitals, physicians, patients or the medical community in general will accept and use any products that we may develop.If we cannot raise additional capital on acceptable terms, we may be unable to complete planned clinical trials, obtain regulatory approvals or
commercialize our product candidates.We will require substantial future capital in order to continue to conduct the research and development, clinical and regulatory activities necessary to bring our
were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.We may become involved in lawsuits to protect or enforce our patents that would be expensive and time consuming.In order to protect or enforce our patent rights, we may initiate patent litigation against third parties in the United States or in foreign countries.
materially adversely affect our business and financial results.We have never manufactured any of our product candidates in commercial quantities, and if we fail to develop an effective manufacturing capability for
expertise and capital resources, including the development of advanced manufacturing techniques and process controls and is subject to local and state planning approvals.
termination of our relationship with Nycomed would have a material adverse impact on our business, financial condition and results of operations.If third-party manufacturers of our products fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our
purchase a raw material that is in limited supply for our clinical trials, or for commercial distribution if we obtain marketing approval of a product candidate, we cannot assure you that one or more
obtain required raw materials for any reason could substantially impair our development activities or the production, marketing and distribution of our products.We have no experience selling, marketing or distributing our products and no internal capability to do so.If we receive regulatory approval to commence commercial sales of any of our products, we will face competition with respect to commercial sales, marketing and
product candidates will require that we provide all the funding for the cost of development and clinical trials or identify collaborators to share in the costs.In
our ultrasound contrast agent and lead product candidate, if approved for marketing and sale, will compete with nuclear stress tests, the current
in the future that could materially adversely affect our business, financial condition and results of operations.Risks Related to Our Common StockWe expect that our stock price will fluctuate significantly.We only recently completed our initial public offering.
Prohibitions on selling shares under these lock-up agreements expired on April 4, 2004.Our directors and management will exercise significant control over our company.Our directors and executive officers and their affiliates collectively control approximately 9.8% of our outstanding common stock, excluding unexercised options
The selected consolidated financial data set forth below are not necessarily indicative of our future results of operations or financial performance.Year Ended December 31,Six Months EndedJune 30,1999200020012002200320032004(in thousands, except per share data)Statement of Operations Data:Operating Expenses:Research and development expense$7,022$9,978$11,536$13,545$14,228$6,248$11,616General and administrative expense1,6222,5173,8933,9064,1731,8552,669Stock-based compensation expense5161,0762,1951,307712459Total operating expenses8,64912,51116,50519,64619,7088,81514,744Equity in loss of joint venture—(12,015)(1,965)(1,183)———Interest and other income (expense), net(492)97193(1,067)(2,215)(1,092)200Net loss(9,141)(24,429)(18,277)(21,896)(21,923)(9,907)(14,544)Accretion of dividends and offering costs on preferred stock(2,604)(4,218)(6,249)(6,666)(5,948)(3,235)—Net loss available to common stockholders$(11,745)$(28,647)$(24,526)$(28,562)$(27,871)$(13,142)$(14,544)Basic and diluted net loss per common share$(27.24)$(64.18)$(50.81)$(35.39)$(6.66)$(10.87)$(1.02)Basic and diluted weighted average common shares outstanding4324464838074,1881,20914,298As of December 31,As ofJune 30,200419992000200120022003(in thousands)Balance Sheet Data:Cash, cash equivalents and short-term investments$2,230$25,275$15,599$7,992$54,562$38,817Working capital(1,498)18,45710,7492,89950,93134,369Total assets5,10429,09224,45713,36758,92445,852Long-term debt, net of current portion4,2881,1045,2901,726205316Redeemable convertible preferred stock32,54085,00997,73991,467——Total stockholders' deficit(35,482)(64,030)(86,228)(85,348)54,37540,33819MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONSYou should read the following discussion in conjunction with our consolidated financial statements, the related notes and other financial
After October 14, 2003, no existing convertible preferred stock is outstanding, and accordingly there will be no further accretion of dividends and offering costs on these shares.27Liquidity and Capital ResourcesHistorically, we have financed our business through the issuance of equity securities, debt financings and equipment leases.
commercial sale of our products unless or until we or current or potential partners complete clinical trials for our products and receive marketing approval from the applicable regulatory authorities.
stock-based compensation expense for stock options issued to employees in fixed amounts with exercise prices at least equal to the fair value of the underlying common stock on the date of grant.
include comparative values of public companies discounted for the risk and limited liquidity provided for in the shares we are issuing, pricing of private sales of our convertible preferred stock,
cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.32BUSINESSOverviewWe are a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using our proprietary porous microparticle
addition, each of these non-employee directors who serves on the Audit Committee will receive on an annual basis an option to purchase 15,000 shares of our common stock
and each other of these non-employee directors will receive on an annual basis an option to purchase 10,000 shares of our common stock, in each case effective immediately following our
exercise price per share of each option was determined by the Compensation Committee on the date of grant to be equal to the fair value per share of common stock.58Option Exercises and Unexercised Option Holdings.The following table sets forth certain information regarding the number and
file a registration statement under the Securities Act at our expense with respect to their shares of common stock, and we are required to use our best efforts to effect that registration.
registration statement under the Securities Act on Form S-3 at our expense with respect to their shares of common stock, and we are required to use our best efforts to effect that
date of issuance of each selling stockholder's warrant, or (ii) the sale of all such shares of common stock covered by the registration statement.Anti-Takeover Effects of Provisions of Delaware Law and Our Certificate of Incorporation and By-lawsWe are subject to the provisions of Section 203 of the Delaware General Corporation Law. Subject to certain exceptions, Section 203 of the Delaware
1,212,849 and 14,294,533 shares as of December 31, 2002 and 2003, respectively12,189142,945Additional paid-in capital34,029,519201,422,784Less treasury stock, 6,027 shares, at cost(361)—Accumulated other comprehensive income288—Deferred stock-based compensation(1,793,404)(1,723,229)Deficit accumulated during the development stage(117,595,947)(145,467,457)Total stockholders' (deficit) equity(85,347,716)54,375,043TOTAL$13,367,061$58,924,253See notes to consolidated financial statements.F-4ACUSPHERE, INC.
issued options to employees to purchase approximately 230,119, and 267,723 shares of common stock during the years ended December 31, 2001 and 2003, respectively, at